NCT07265466

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban in Healthy Volunteers.

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Onconic Therapeutics Inc. · Industry
• Sex: All
• Age: 19 Years – 64 Years
• Healthy volunteers: Accepted

Summary

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Conditions

• Drug Drug Interaction (DDI)

Interventions

Type	Name	Description
DRUG	JP-1366 and clopidogrel	A randomized, open label, multiple-dosing, 6-sequence, 3-period, 3-treatment, crossover design
DRUG	JP-1366 and aspirin	An open-label, multiple-dosing, fixed sequence, 3-period design
DRUG	JP-1366 and atorvastatin	An open-label, multiple-dosing, fixed sequence, 3-period design Period 1: Atorvastatin
DRUG	JP-1366 and apixaban	An open-label, multiple-dosing, fixed sequence, 3-period design

Timeline

• Start date: 2025-11-17
• Primary completion: 2026-03-30
• Completion: 2026-03-30
• First posted: 2025-12-04
• Last updated: 2025-12-04

Locations

1 site across 1 country: South Korea